title: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate the antitumor activity and safety of YM155, a novel, small-molecule suppressor of survivin, as single-agent therapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients with stage IIIb/IV NSCLC who had experienced treatment failure during one or two prior chemotherapy regimens (at least one of which was platinum based) received YM155 as a continuous intravenous infusion (4.8 mg/m(2)/d) over 168 hours followed by observation for 14 days in 21-day treatment cycles. The primary end point was objective tumor response rate (ORR). Secondary end points included duration of stable disease (SD), progression-free survival (PFS), overall survival (OS), safety and pharmacokinetic profiles, and pharmacodynamic evaluations.
  
  
  RESULTS
  Thirty-seven patients received YM155. Two patients achieved a confirmed partial response, with an ORR of 5.4% (95% CI, 0.7% to 18.2%). An additional 14 patients (37.8%) achieved SD resulting in a disease control rate of 43.2% (95% CI, 27.1% to 60.5%). Median duration of PFS was 1.7 months (95% CI, 1.3 to 2.8 months). Median duration of OS was 6.6 months (95% CI, 4 to 12.2 months), with a 1-year survival rate of 35.1%. Treatment with YM155 was well tolerated with the majority of treatment discontinuations not treatment related.
  
  
  CONCLUSIONS
  YM155 exhibited modest single-agent activity in patients with refractory, advanced NSCLC. A favorable safety/tolerability profile was reported. Further evaluation of YM155 in combination with chemotherapy and other targeted agents may be warranted.
authors.affiliation: Vrije Universiteit Medical Center, Amsterdam, The Netherlands. giacconeg@mail.nih.gov
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giaccone
authors.forename: Petr
authors.initials: P
authors.lastname: Zatloukal
authors.forename: Jaromir
authors.initials: J
authors.lastname: Roubec
authors.forename: Karijn
authors.initials: K
authors.lastname: Floor
authors.forename: Jaromir
authors.initials: J
authors.lastname: Musil
authors.forename: Milan
authors.initials: M
authors.lastname: Kuta
authors.forename: Rob J
authors.initials: RJ
authors.lastname: van Klaveren
authors.forename: Subhash
authors.initials: S
authors.lastname: Chaudhary
authors.forename: Adrie
authors.initials: A
authors.lastname: Gunther
authors.forename: Setareh
authors.initials: S
authors.lastname: Shamsili
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D009285:Naphthoquinones; D000077022:Survivin; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D000077022:Survivin; C523798:sepantronium